Germany's Merck KGaA drops ms drug
German drug maker Merck KGaA says it is dropping its approval bids for multiple sclerosis drug Cladribine and will take a €20 billion charge to earnings in the second quarter.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany , today announced a strategic collaboration with US ranked Brigham and Women's Hospital in Boston , to advance basic and clinical research in multiple sclerosis, with the goal of generating new and innovative discoveries that advance treatment for people living with this condition.